Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Publication Information:
      Taylor & Francis Group, 2019.
    • Publication Date:
      2019
    • Collection:
      LCC:Internal medicine
    • Abstract:
      Background: Drug-eluting stent(DES) implantation is the main interventional treatment for coronary artery disease, and dual antiplatelet therapy(DAPT) remains the gold standard strategy to prevent ischemic events. However, the optimal duration of DAPT after DES implantation remains controversial. Therefore, we aimed to evaluate the best duration of DAPT following DES implantation. Method: We searched PubMed, Embase, Cochrane Library, and clinicaltrials.gov for all randomized clinical trials(RCTs) that compared different durations of DAPT after DES implantation. Major adverse cardiac events(MACE) and major bleeding were the primary and secondary outcomes, respectively. Results: We included 16 RCTs (n = 42,993). The mean age of included patients was 63.1 ± 10.1. The primary outcome was statistically significant for lower MACE in patients who received DAPT for 24–48 months (mo) following DES when compared with those who received 3–6 mo of DAPT (odds ratio [OR] 0.75; 95% credible interval [CI] 0.58–0.97). There was nonstatistically significant difference in MACE when comparing those who received 12 mo of DAPT to those taking either 3–6 mo of DAPT (OR 0.86; 95% CI 0.69–1.08) or 24–48 mo of DAPT (OR 0.87; 95% CI 0.72–1.05). In contrast, major bleeding was significantly lower in those who received 3–6 mo of DAPT (OR 0.32; 95% CI 0.17–0.54) and 12 mo of DAPT (OR 0.43; 95% CI 0.27–0.63) than in those who received 24–48 mo of DAPT. Conclusion: In patients who undergo DES implantation, a longer duration of DAPT is associated with lower MACE, despite the increased risk of major bleeding events. Therefore, individualizing the duration of DAPT after DES according to the patient’s risk of bleeding and recurrent ischemia is recommended.
    • File Description:
      electronic resource
    • ISSN:
      2000-9666
      20009666
    • Relation:
      https://doaj.org/toc/2000-9666
    • Accession Number:
      10.1080/20009666.2018.1562853
    • Rights:
      Journal Licence: CC BY-NC
    • Accession Number:
      edsdoj.be6c817f74ab45b3824db4427bfa45eb
  • Citations
    • ABNT:
      MAHMOUD BARBARAWI et al. Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials. Journal of Community Hospital Internal Medicine Perspectives, [s. l.], n. 1, p. 9, 2019. DOI 10.1080/20009666.2018.1562853. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsdoj&AN=edsdoj.be6c817f74ab45b3824db4427bfa45eb&custid=s8280428. Acesso em: 8 abr. 2020.
    • AMA:
      Mahmoud Barbarawi, Babikir Kheiri, Yazan Zayed, et al. Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials. Journal of Community Hospital Internal Medicine Perspectives. 2019;(1):9. doi:10.1080/20009666.2018.1562853.
    • APA:
      Mahmoud Barbarawi, Babikir Kheiri, Yazan Zayed, Ahmed Aburahma, Mohammed Osman, Owais Barbarawi, Michael Hicks, Mustafa Hassan, Mohammad L. Alkotob, & Ghassan Bachuwa. (2019). Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials. Journal of Community Hospital Internal Medicine Perspectives, 1, 9. https://doi.org/10.1080/20009666.2018.1562853
    • Chicago/Turabian: Author-Date:
      Mahmoud Barbarawi, Babikir Kheiri, Yazan Zayed, Ahmed Aburahma, Mohammed Osman, Owais Barbarawi, Michael Hicks, Mustafa Hassan, Mohammad L. Alkotob, and Ghassan Bachuwa. 2019. “Best Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation: An Updated Network Meta-Analysis of Randomized Controlled Trials.” Journal of Community Hospital Internal Medicine Perspectives, no. 1: 9. doi:10.1080/20009666.2018.1562853.
    • Harvard:
      Mahmoud Barbarawi et al. (2019) ‘Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials’, Journal of Community Hospital Internal Medicine Perspectives, (1), p. 9. doi: 10.1080/20009666.2018.1562853.
    • Harvard: Australian:
      Mahmoud Barbarawi, Babikir Kheiri, Yazan Zayed, Ahmed Aburahma, Mohammed Osman, Owais Barbarawi, Michael Hicks, Mustafa Hassan, Mohammad L. Alkotob & Ghassan Bachuwa 2019, ‘Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials’, Journal of Community Hospital Internal Medicine Perspectives, no. 1, p. 9, viewed 8 April 2020, .
    • MLA:
      Mahmoud Barbarawi, et al. “Best Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation: An Updated Network Meta-Analysis of Randomized Controlled Trials.” Journal of Community Hospital Internal Medicine Perspectives, no. 1, 2019, p. 9. EBSCOhost, doi:10.1080/20009666.2018.1562853.
    • Chicago/Turabian: Humanities:
      Mahmoud Barbarawi, Babikir Kheiri, Yazan Zayed, Ahmed Aburahma, Mohammed Osman, Owais Barbarawi, Michael Hicks, Mustafa Hassan, Mohammad L. Alkotob, and Ghassan Bachuwa. “Best Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation: An Updated Network Meta-Analysis of Randomized Controlled Trials.” Journal of Community Hospital Internal Medicine Perspectives, no. 1 (2019): 9. doi:10.1080/20009666.2018.1562853.
    • Vancouver/ICMJE:
      Mahmoud Barbarawi, Babikir Kheiri, Yazan Zayed, Ahmed Aburahma, Mohammed Osman, Owais Barbarawi, et al. Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials. Journal of Community Hospital Internal Medicine Perspectives [Internet]. 2019 [cited 2020 Apr 8];(1):9. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsdoj&AN=edsdoj.be6c817f74ab45b3824db4427bfa45eb&custid=s8280428